All Stories

  1. Exploring the dichotomy of the mesenchymal stem cell secretome: Implications for tumor modulation via cell-signaling pathways
  2. Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine
  3. Association Study between rs10486567, rs13149290, rs1545985 and rs6983267 with Incidence of Prostate Adenocarcinoma Among Iranians
  4. Reproducibility and repeatability of quantitative T2 and T2* mapping of osteosarcomas in a mouse model
  5. Regulation of Cellular-Signaling Pathways by Mammalian Proteins Containing Bacterial EPIYA or EPIYA-Like Motifs Predicted to be Phosphorylated
  6. Integrating DNA methylation and gene expression data in a single gene network using the iNETgrate package
  7. Novel Clinically Translatable Iron Oxide Nanoparticle for Monitoring Anti-CD47 Cancer Immunotherapy
  8. Investigating the Association of rs4962416 and rs6465657 with Prostate Adenocarcinoma in the Iranian Population
  9. Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration
  10. Co-Clinical Imaging Metadata Information (CIMI) for Cancer Research to Promote Open Science, Standardization, and Reproducibility in Preclinical Imaging
  11. Association study between rs1571801 and rs16260 with prostate adenocarcinoma predisposition in Iranian population
  12. Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials
  13. MegaPro, a clinically translatable nanoparticle for in vivo tracking of stem cell implants in pig cartilage defects
  14. The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment
  15. RNA‐sequencing for transcriptional profiling of whole blood in early stage and metastatic pancreatic cancer patients
  16. Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer
  17. Identification of hub genes, modules and biological pathways associated with lung adenocarcinoma: A system biology approach
  18. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects
  19. p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis
  20. Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis
  21. CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
  22. CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
  23. Identification of potential common molecular factors of pancreatic cancer and diabetes mellitus using microarray data analysis combined with bioinformatics techniques and experimental validation
  24. Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients
  25. Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer
  26. Immunotherapy‑based combinations versus standard first‑line and hypothyroidism risk
  27. Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics
  28. The relationship between KLK3 rs17632542 and PRNCR1 rs16901979 polymorphisms with susceptibility to prostate cancer
  29. High GD2 expression defines breast cancer cells with enhanced invasiveness
  30. Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
  31. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis
  32. Dendritic cell/cytokine‐induced killer cell‐based immunotherapy in lung cancer: What we know and future landscape
  33. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
  34. CD44 epithelial isoform inversely associates with invasive characteristics of colorectal cancer
  35. Co‐expression of TLR ‐9 and MMP ‐13 is associated with the degree of tumour differentiation in prostate cancer
  36. Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy
  37. Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma
  38. Induction of miR-31 causes increased sensitivity to 5-FU and decreased migration and cell invasion in gastric adenocarcinoma
  39. Association of homeobox B13 (HOXB13) gene variants with prostate cancer risk in an Iranian population
  40. Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol
  41. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients
  42. Association of Homeobox B13 (HOXB13) Gene Variants with Prostate Cancer Risk in Iranian Population
  43. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol
  44. Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention
  45. Resisting resistance to cancer immunotherapy
  46. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent
  47. Lgr5High/DCLK1High phenotype is more common in early stage and intestinal subtypes of gastric carcinomas
  48. DNA Microarray
  49. Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer
  50. Antimicrobial Peptides As Biologic and Immunotherapeutic Agents against Cancer: A Comprehensive Overview
  51. Increased Expression of ALDH1A1 in Prostate Cancer is Correlated With Tumor Aggressiveness
  52. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells
  53. Cancer stem cell research in Iran: potentials and challenges
  54. Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma
  55. Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
  56. Lung cancer and β-glucans: review of potential therapeutic applications
  57. Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas
  58. Differential role of Wnt signaling and base excision repair pathways in gastric adenocarcinoma aggressiveness
  59. Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma
  60. Accuracy of c-KIT in lung cancer prognosis; a systematic review protocol" instead of c-KIT Expression in Lung Cancer Prognostic Evaluation - a Systematic Review Protocol
  61. Comparative Expression Analysis of Putative Cancer Stem Cell Markers CD44 and ALDH1A1 in Various Skin Cancer Subtypes
  62. Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol
  63. Evaluation of anaplastic lymphoma kinase expression in nonsmall cell lung cancer;a tissue microarray analysis
  64. Erratum: Evaluation of anaplastic lymphoma kinase expression in nonsmall cell lung cancer; a tissue microarray analysis
  65. Comparative gene-expression profiling of CD133+ and CD133- D10 melanoma cells
  66. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes
  67. Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer
  68. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549